Highlights
- Total Revenue (TTM)
- $7.68M
- Gross Profit (TTM)
- -$5.97M
- EBITDA (TTM)
- -$39.51M
- Year Range
- $0.00 - $0.18
- Target Price
- $5.00
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in T2 Biosystems, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
T2 Biosystems, Inc. (TTOO) has returned -94.00% so far this year and -99.76% over the past 12 months. Over the last ten years, TTOO has returned -84.90% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
T2 Biosystems, Inc.
- 1D
- 50.00%
- 1M
- -86.36%
- YTD
- -94.00%
- 6M
- -97.58%
- 1Y
- -99.76%
- 3Y*
- -98.13%
- 5Y*
- -96.72%
- 10Y*
- -84.90%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Aug 7, 2014, TTOO's average daily return is +3.24%, while the average monthly return is -5.02%.
Historically, 34% of months were positive and 66% were negative. The best month was Sep 2025 with a return of +210.0%, while the worst month was Jul 2025 at -87.1%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 10 months.
On a daily basis, TTOO closed higher 42% of trading days. The best single day was Dec 24, 2025 with a return of +3,733.3%, while the worst single day was Dec 23, 2025 at -97.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -56.00% | 0.00% | -86.36% | -94.00% | |||||||||
| 2025 | -48.81% | -41.86% | -1.60% | -6.50% | 40.00% | -13.60% | -87.06% | -77.78% | 210.00% | -11.29% | 10.00% | -58.68% | -98.81% |
| 2024 | -28.29% | 12.00% | -40.48% | 11.83% | 53.20% | 3.89% | -8.61% | -34.63% | -38.24% | -55.54% | -34.70% | -26.57% | -93.31% |
| 2023 | 10.56% | -60.83% | -25.20% | -28.26% | -72.73% | -21.56% | 108.92% | 112.20% | -29.42% | -73.25% | -40.10% | 77.26% | -95.58% |
| 2022 | -18.64% | 3.60% | 20.46% | -29.40% | -45.30% | -20.21% | -25.33% | 1.58% | -7.76% | -67.26% | -10.27% | -14.46% | -94.50% |
| 2021 | 60.48% | 15.08% | -29.26% | -14.81% | 0.72% | -14.39% | -13.45% | -9.27% | -2.07% | -15.37% | -19.97% | -16.72% | -58.37% |
Benchmark Metrics
T2 Biosystems, Inc. has an annualized alpha of 300488.00%, beta of 0.21, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since August 08, 2014.
- This stock participated in 249.20% of S&P 500 Index downside but only -156.25% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.21 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 300,488.00%
- Beta
- 0.21
- R²
- 0.00
- Upside Capture
- -156.25%
- Downside Capture
- 249.20%
Return for Risk
Risk / Return Rank
TTOO ranks 51 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for T2 Biosystems, Inc. (TTOO) and compare them to a chosen benchmark (S&P 500 Index).
| TTOO | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.02 | 0.90 | -0.92 |
Sortino ratioReturn per unit of downside risk | 24.55 | 1.39 | +23.16 |
Omega ratioGain probability vs. loss probability | 4.87 | 1.21 | +3.66 |
Calmar ratioReturn relative to maximum drawdown | -1.00 | 1.40 | -2.40 |
Martin ratioReturn relative to average drawdown | -1.25 | 6.61 | -7.86 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore TTOO risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the T2 Biosystems, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the T2 Biosystems, Inc. was 100.00%, occurring on Mar 18, 2026. The portfolio has not yet recovered.
The current T2 Biosystems, Inc. drawdown is 100.00%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -100% | Jan 15, 2015 | 2809 | Mar 18, 2026 | — | — | — |
| -40.24% | Sep 2, 2014 | 37 | Oct 22, 2014 | 57 | Jan 14, 2015 | 94 |
| -11.06% | Aug 21, 2014 | 1 | Aug 21, 2014 | 6 | Aug 29, 2014 | 7 |
| -6.42% | Aug 8, 2014 | 1 | Aug 8, 2014 | 2 | Aug 12, 2014 | 3 |
| -1.68% | Aug 15, 2014 | 1 | Aug 15, 2014 | 1 | Aug 18, 2014 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of T2 Biosystems, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how T2 Biosystems, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |